Purchase this article with an account.
Behnam Sharareh, Mehran Taban, Josh Wallsh, Elijah Moon, Ron P. Gallemore; Recalcitrant Macular Edema Following Anti-vegf Injections Is Responsive To An Intravitreal Dexamethasone Implant In Retinal Vein Occlusion. Invest. Ophthalmol. Vis. Sci. 2011;52(14):6066.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To test the efficacy of an intravitreal dexamethasone implant in patients with retinal vein occlusions for macular edema resistant to anti-VEGF therapy.
A retrospective chart review followed by thorough analysis was performed for 6 patients with retinal vein occlusion who received anti-VEGF intravitreal injections prior to treatment with the intravitreal dexamethasone implant.
An average visual acuity improvement of 0.1138 on the logMAR scale and a reduction in central macular thickness of 72 microns was noted following an intravitreal dexamethasone implant compared to data obtained post anti-VEGF therapy for the same patient. Steroid induced glaucoma was observed in 2 patients who experienced a 3 mmHg average increase in intraocular pressure 4 weeks following injection of the dexamethasone implant. This was an uncomplicated side effect and was managed easily with topical drops.
Residual macular edema following anti-VEGF injection is reduced by subsequent intravitreal dexamethasone implant injection. This FDA-approved implant should be considered in such recalcitrant cases.
This PDF is available to Subscribers Only